1. Reduced progression of bone erosion in cytomegalovirus seropositive rheumatoid arthritis patients
- Author
-
Alain Cantagrel, Adeline Ruyssen-Witrand, Bernard Combe, J. Izopet, Benjamin Rauwel, Delphine Nigon, J.-F. Boyer, Jean-Luc Davignon, Arnaud Constantin, F. Abravanel, Yannick Degboé, Centre de Physiopathologie Toulouse Purpan (CPTP), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre de Rhumatologie toulouse [CHU Toulouse], CHU Toulouse [Toulouse]-Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse], Faculté de Médecine [Rangueil], Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse], Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps (LEASP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire de Virologie [Toulouse], Département de Rhumatologie[Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Lapeyronie, PINIER, CHRISTINE, Université Fédérale Toulouse Midi-Pyrénées, Centre de Rhumatologie [CHU Toulouse], Pôle Inflammation, infection, immunologie et loco-moteur [CHU Toulouse] (Pôle I3LM Toulouse), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Laboratoire Virologie [CHU Toulouse], Institut Fédératif de Biologie (IFB), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Pôle Biologie [CHU Toulouse], and Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)
- Subjects
Male ,0301 basic medicine ,Human cytomegalovirus ,lcsh:Diseases of the musculoskeletal system ,Multivariate analysis ,viruses ,Bone erosion ,Gastroenterology ,Serology ,Arthritis, Rheumatoid ,Cohort Studies ,0302 clinical medicine ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,Longitudinal Studies ,Prospective Studies ,MESH: Longitudinal Studies ,MESH: Cohort Studies ,MESH: Middle Aged ,Confounding ,virus diseases ,Middle Aged ,MESH: Cytomegalovirus Infections / complications ,Rheumatoid arthritis ,Cytomegalovirus Infections ,Cohort ,[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,Disease Progression ,Female ,MESH: Disease Progression ,Research Article ,Adult ,medicine.medical_specialty ,Congenital cytomegalovirus infection ,03 medical and health sciences ,Internal medicine ,medicine ,Humans ,MESH: Arthritis, Rheumatoid / pathology ,030203 arthritis & rheumatology ,Inflammation ,MESH: Humans ,business.industry ,ESPOIR cohort ,MESH: Adult ,biochemical phenomena, metabolism, and nutrition ,medicine.disease ,Rheumatology ,MESH: Male ,MESH: Prospective Studies ,MESH: Arthritis, Rheumatoid / virology ,030104 developmental biology ,lcsh:RC925-935 ,business ,MESH: Female - Abstract
Background Human cytomegalovirus (HCMV) seropositivity has been associated with higher inflammation during rheumatoid arthritis (RA). However, no data are available on the impact of HCMV seropositivity on bone erosion progression during RA. Methods We selected 487 individuals of ESPOIR cohort who fulfilled the 2010 ACR/EULAR criteria for RA. HCMV serology for these patients was determined using Architect CMV IgG assay. Baseline and 1-year central X-ray reading using modified Total Sharp Score (mTSS), Erosion Sharp Score, and joint space narrowing Sharp score were used to quantify structural damage progression. We performed univariate and multivariate analyses to investigate the association between HCMV status and bone erosion progression. Results We analyzed 273 HCMV seropositive (HCMV+) and 214 HCMV seronegative (HCMV−) RA patients. At inclusion, HCMV+ patients were less frequently ACPA+ (49.8% versus 58.9%, p p 1 point) was lower in HCMV+ patients (16.1% versus 25.2%, p = 0.0128) in comparison with HCMV−. HCMV+ status remained independently associated with lower bone erosion progression in multivariate analysis. Conclusions Our findings suggest that, independently of other confounding factors, HCMV seropositivity is associated with a lower progression of bone erosion during RA.
- Published
- 2020
- Full Text
- View/download PDF